FDA Approves Abbott's FreeStyle Navigator(R) Continuous Glucose Monitor... ( New Tool Uniquely Provides Minute-by...)

FDA Approves Abbott's FreeStyle Navigator(R) Continuous Glucose Monitoring System

Date:3/13/2008

New Tool Uniquely Provides Minute-by-Minute and Trend Information That Can

Lead to Proactive Diabetes Management

ABBOTT PARK, Ill., March 13 /PRNewswire-FirstCall/ -- The Food and Drug Administration (FDA) has approved the FreeStyle Navigator(R) Continuous Glucose Monitoring System (http://www.continuousmonitor.com/) in the United States for people with diabetes. Designed to discretely and continuously measure glucose levels through a sensor in the back of the upper arm or abdomen (http://www.abbott.com/static/application/audiovideo/video_freestyle.wmv), Abbott's FreeStyle Navigator system provides minute-by-minute information about which way and how quickly blood sugar levels are changing. This information can lead to proactive adjustments that can result in tighter glucose ranges. Before adjusting therapy for diabetes management based on the results and alarms from the FreeStyle Navigator system, traditional blood glucose tests must be performed.

The FreeStyle Navigator system will be available in the second quarter of 2008 by prescription only. It received CE Mark (http://www.abbott.com/global/url/pressRelease/en_US/60.5:5/Press_Release_0 478 .htm) in June 2007 and has been available outside the United States since September 2007.

"Understanding glucose trends, with the goal of minimizing fluctuations, is an important part of improving the management of diabetes," said endocrinologist and Director of the International Diabetes Center Richard Bergenstal, M.D. "We are always looking for new tools like these to enable people with diabetes to continuously monitor their glucose levels, putting them on the offense, not defense, so they can take action before a hig
'/>"/>

2

GOOD

Page: 1 2 3 4 5
Related medicine news :

1. FDA Approves Aloxi(R) (Palonosetron HCL) Injection for Prevention of Postoperative Nausea and Vomiting
2. FDA Approves Luvox(R) CR (Fluvoxamine Maleate) Extended-Release Capsules for the Treatment of Social Anxiety Disorder (SAD) and Obsessive Compulsive Disorder (OCD)
3. FDA Approves NEXIUM(R) for the Treatment of Short-Term GERD in Children 1 to 11 Years Old
4. U.S. Court Approves AK Steels VEBA Health Care Settlement With Middletown Works Retirees
5. Securian Board Approves 8 Officer Promotions
6. MGT Capital Investments, Inc. Approves Share Buyback Program
7. Kaiser Permanente Approves $29 Million in Community Benefit Grants
8. Otter Tail Corporation Reports Record Revenues and Net Income From Continuing Operations for 2007; Earnings Per Share of $1.78; Board Approves Dividend Increase
9. Pennsylvania Attorney General Approves Vincentian Collaborative System-Marian Manor Integration
10. FDA Approves ASMANEX (R) TWISTHALER(R) (Mometasone Furoate Inhalation Powder) for the Once Daily Maintenance Treatment of Asthma in Children Ages 4-11
11. FDA Approves Additional Indication for Astellas MYCAMINE(R)

Post Your Comments:

FDA Approves Abbott's FreeStyle Navigator(R) Continuous Glucose Monitor...( New Tool Uniquely Provides Minute-by...),Health